The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.
Dr. Tan studies transcriptional regulation during normal development and disease. This involves the interplay of multiple transcription and epigenetic factors in a 3D chromosomal environment. Using experimental genomics and computational modeling, Dr. Tan investigates transcriptional regulatory networks underlying embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.
John M. Maris, MD, is leading a pediatric immuno-oncology Center for Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers with support from the NCI Moonshot Initiative.
The Hogarty Laboratory studies the childhood tumor neuroblastoma. This enigmatic tumor is responsible for 15% of all childhood cancer deaths despite the use of highly intensive therapies, and survivors often suffer lifelong toxicities from their treatments. New approaches are needed to improve outcomes, and the lab seeks to understand the biology driving aggressive tumor behavior, and identify unique tumor-specific vulnerabilities.
The Tan Laboratory studies the fundamental question of transcriptional regulation during normal development and disease. It involves a complex interplay of multiple transcription factors and epigenetic factors in the context of a three-dimensional chromosomal environment. Using experimental genomics and computational modeling, the lab has been studying transcriptional regulatory networks underlying embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.
The Mossé Laboratory studies the role of the anaplastic lymphoma kinase (ALK) oncogene in the initiation and progression of neuroblastoma, with a focus on developing innovative therapeutic strategies for patients with this often lethal disease.